Regulation of TGF-β1 expression by Androgen Deprivation Therapy of prostate cancer

Cancer Letters

Volumn 318, Issue 2, 2012, Pages 135-144

  Fuzio, Paolo ^a   Ditonno, Pasquale ^b   Rutigliano, Monica ^b   Battaglia, Michele ^b   Bettocchi, Carlo ^b   Loverre, Antonia ^b   Grandaliano, Giuseppe ^b   Perlino, Elda ^a  

^a CNR   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

ADT; Gene expression; Prostate cancer; TGF

Indexed keywords

BICALUTAMIDE; GOSERELIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

AGED; ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84858155560     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.034     Document Type: Article

References (44)

1. Reynolds A.R., Kyprianou N. Growth factor signaling in prostatic growth: significance in tumor development and therapeutic targeting. Brit. J. Pharmacol. 2006, 147:S144-S152.
2. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-β) in prostate cancer. Eur. J. Cancer 2005, 41:846-857.
3. Elliott R.L., Blode G.C. Role of transforming growth factor beta in human cancer. J. Clin. Oncol. 2005, 23:2078-2093.
4. Dennler S., Goumans M.J., ten Dijke P. Transforming growth factor β signal transduction. J. Leukoc. Biol. 2002, 71:731-739.
5. Massagué J., Gomis R.R. The logic of TGF-beta signaling. FEBS Lett. 2006, 580:2811-2820.
6. Yan Z., Winawer S., Friedman E. Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J. Biol. Chem. 1994, 269:13231-13237.
7. Wilkes M.C., Mitchell H., Penheiter S.G., Dore J.J., Suzuki K., Edens M., Sharma D.K., Pagano R.E., Leof E.B. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res. 2005, 65:10431-10440.
8. Wikstrom P., Damber J.E., Bergh A. Role of transforming growth factor-pi in prostate cancer. Microsc. Res. Tech. 2001, 52:411-419.
9. Zhu M.L., Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocrine-Rel. Cancer 2008, 15:841-849.
10. Yoon G., Kim J.Y., Choi Y.K., Won Y.S., Lim I.K. Direct activation of TGF-beta1 transcription by androgen and androgen receptor complex in Huh7 human hepatoma cells and its tumour in nude mice. J. Cell. Biochem. 2006, 97:393-411.
11. Lee C., Sintich M.S., Mathews P.E., Shash H.A., Kundu D.S., Perry T.K., Cho S.J., Ilio Y.K., Cronauer V.M., Janulis L., Sensibar A.J. Transforming growth factor-P in benign and malignant prostate. The Prostate 1999, 39:285-290.
12. Feldman B.J., Feldman D. The development of androgen independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
13. Montironi R., Mazzucchelli R., Lopez-Beltran A., Cheng L., Scarpelli M. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat. Clin. Pract. Urol. 2007, 4(6):321-332.
14. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 1992, 23:273-279.
15. L.H. Sobin, I.D. Fleming, TNM Classification of Malignant Tumors, fifth ed. (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer, Cancer 80 (9) (1997) 1803-1804.
16. Perlino E., Lovecchio M., Vacca R.A., Fornaro M., Moro L., Ditonno P., Battaglia M., Selvaggi F.P., Mastropasqua M.G., Bufo P., Languino L.R. Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am. J. Pathol. 2000, 157:1727-1734.
17. Derynck R., Jarret J.A., Chen E.Y., Eaton D.H., Bell J.R., Assoian R.K., Roberts A.B., Sporn M.B., Goeddel D.V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985, 316:701-705.
18. Centrella M., Ji C., Casinghino S., McCarthy T.L. Rapid flux in transforming growth factor-beta receptors on bone cells. J. Biol. Chem. 1996, 271:18616-18622.
19. Bhatia P., Taylor W.R., Greenberg A.H., Wright J.A. Comparison of glyceraldehyde-3- phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for northern blot analysis of cell lines of varying malignant potential. Anal. Biochem. 1994, 216:223-226.
20. Moro L., Greco M., Ditonno P., Battaglia M., Marra E., Perlino E. Transcriptional regulation of the beta1C integrin splice variant in human prostate adenocarcinoma. Int. J. Oncol. 2003, 23:1601-1606.
21. Taichman R.S., Loberg R.D., Mehra R., Pienta K.J. The evolving biology and treatment of prostate cancer. J. Clin. Invest. 2007, 117:2351-2361.
22. Fuzio P., Lucarelli G., Perlino E., Battaglia M., Bettocchi C., Selvaggi F.P., Ditonno P. Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer. Oncol. Reports 2009, 22(2):327-335.
23. Perlino E., Ciampolillo A., Maiorano E., Pannone E., Viale G., Giorgino R., Marra E. Transforming growth factor beta1 (TGF-beta1) expression in proliferating thyroid disease. Int. J. Oncol. 1996, 9:83-88.
24. Perlino E., Ciampolillo A., Maiorano E., Marra E. TGF-beta expression in thyroid proliferating disease. Int. J. Biol. Markers 1996, 11:124-125.
25. Perlino E., Loverro G., Maiorano E., Giannini T., Cazzolla A., Napoli A., Fiore M.G., Ricco R., Marra E., Selvaggi L. Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma. Brit. J. Cancer 1998, 77:1260-1266.
26. Perlino E., Moro L., Loverro G., Maiorano E., Selvaggi L., Marra E. Role of the growth factors IGF-1 and TGF-beta 1 in the endometrial adenocarcinoma. Int. J. Med. Biol. Env. 2001, 29:193-200.
27. Lovecchio M., Maiorano E., Vacca R.A., Loverro G., Fanelli M., Resta L., Stefanelli S., Selvaggi L., Marra E., Perlino E. Beta 1C integrin expression in human endometrial proliferative diseases. Am. J. Pathol. 2003, 163(6):2543-2553.
28. Loverro G., Cormio G., Perlino E., Vicino M., Cazzolla A., Selvaggi L. Transforming growth factor-beta1 in hemangioma of the ovary. Gynecol. Obstet. Invest. 1998, 46:210-213.
29. Loverro G., Perlino E., Maiorano E., Cormio G., Ricco R., Marra E., Nappi L., Giannini T., Selvaggi L. TGF-beta 1 and IGF-1 expression in atrophic post-menopausal endometrium. Maturitas 1999, 31:179-184.
30. Vacca R.A., Marra E., Loverro G., Maiorano E., Napoli A., Lovecchio M., Selvaggi L., Perlino E. Differential expression of beta 1c integrin messenger ribonucleic acid and protein levels in human endometrium and decidua during the menstrual cycle and pregnancy. J. Clin. Endocrinol. Metab. 2003, 88:720-729.
31. Vacca R.A., Moro L., Maiorano E., Selvaggi L., Marra E., Perlino E. Alternatively spliced variants of B1 integrin are involved in the modulation of human endometrial transformation in different physiological/pathological conditions. Recent Res. Devel. Proteins 2004, 2:25-47.
32. Moro L., Greco M., Ditonno P., Battaglia M., Marra E., Perlino E. Transcriptional regulation of the beta1C integrin splice variant in human prostate adenocarcinoma. Int. J. Oncol. 2003, 23(6):1601-1606.
33. Moro L., Perlino E., Marra E., Languino L.R., Greco M. Regulation of beta1C and beta1A integrin expression in prostate carcinoma cells. J. Biol. Chem. 2004, 279:1692-1702.
34. Moro L., Greco M., Maiorano E., Selvaggi L., Marra E., Perlino E. Transcriptional regulation of beta1 integrin expression in the physio/pathological states of human endometrial tissues. Int. J. Oncol. 2005, 26(2):457-465.
35. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr. Opin. Endocrinol. Diabetes Obes. 2007, 14:247-254.
36. Sinha A.A., Blackard C.E., Seal US. A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer 1977, 40(6):2836-2850.
37. Kerr J.F., Searle J. Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows. Arch. B Cell Pathol. 1973, 13(2):87-102.
38. Wikstrom P., Lindh G., Bergh A., Damber J.E. Alterations of transforming growth factor b1 (TGF-b1) and TGFb receptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines. Urol. Res. 1999, 27:185-193.
39. Wikstrom P., Westin P., Stattin P., Damber J.E., Bergh A. Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumour cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 1999, 38:268-277.
40. Kyprianou N., English H.F., Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 1990, 50:3748-3753.
41. Gerdes M.J., Larsen M., McBride L., Dang T.D., Lu B., Rowley D. Localization of transforming growth factor-b1 and type II receptor in developing normal human prostate and carcinoma tissues. J. Histochem. Cytochem. 1998, 46:379-388.
42. Shariat S.F., Menesses-Diaz A., Kim I.Y., Muramoto M., Wheeler T.M., Slawin K.M. Tissue expression of transforming growth factor-13 1 and its receptors: correlation with pathololic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63:1191-1197.
43. Rodri{dotless}́guez-Berriguete G., Galvis L., Fraile B., de Bethencourt F.R., Marti{dotless}́nez-Onsurbe P., Olmedilla G., Paniagua R., Royuela M., caspase-3 Immunoreactivity to, caspase-7 caspase-8 and caspase-9 forms is frequently lost in human prostate tumors. Hum. Pathol. 2012, 43(2):229-237.
44. Fuzio P., Ditonno P., Lucarelli G., Battaglia M., Bettocchi C., Senia T., Perlino E. Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. Int. J. Oncol. 2011, 39(5):1233-1242.